0000000000361932

AUTHOR

Javier Segovia

showing 2 related works from this author

Clinical characteristics and determinants of the phenotype in TMEM43 arrhythmogenic right ventricular cardiomyopathy type 5.

2020

Arrhythmogenic right ventricular cardiomyopathy type V (ARVC-5) is the most aggressive heterozygous form of ARVC. It is predominantly caused by a fully penetrant mutation (p.S358L) in the nondesmosomal gene TMEM43-endemic to Newfoundland, Canada. To date, all familial cases reported worldwide share a common ancestral haplotype. It is unknown whether the p.S358L mutation by itself causes ARVC-5 or whether the disease is influenced by genetic or environmental factors. The purpose of this study was to examine the phenotype, clinical course, and the impact of exercise on patients with p.S358L ARVC-5 without the Newfoundland genetic background. We studied 62 affected individuals and 73 noncarrie…

AdultMalemedicine.medical_specialtyDNA Mutational AnalysisMutation MissenseDisease030204 cardiovascular system & hematologyVentricular Function LeftRight ventricular cardiomyopathySudden cardiac deathElectrocardiography03 medical and health sciences0302 clinical medicinePhysiology (medical)Internal medicinemedicineGeneticsHumans030212 general & internal medicineExerciseArrhythmogenic Right Ventricular DysplasiaEjection fractionTMEM43business.industryIncidence (epidemiology)HaplotypeMembrane ProteinsStroke VolumeDNAmedicine.diseasePhenotypePedigree3. Good healthPhenotypeMutation (genetic algorithm)CardiologyFemaleCardiology and Cardiovascular MedicinebusinessArrhythmogenic right ventricular cardiomyopathyArrhythmia
researchProduct

Counseling Patients with a Glioblastoma Amenable Only for Subtotal Resection: Results of a Multicenter Retrospective Assessment of Survival and Neuro…

2017

Background Patients with a glioblastoma (GB) amenable only for subtotal resection (STR) represent a challenge in patient counseling. Our objective was to assess impact of extent of resection (EoR) on survival and clinical outcome of these patients. Methods We performed a retrospective multicenter assessment. Patients receiving an intended STR in 3 centers with unilocular, primary, highly eloquent GB who received the same adjuvant treatment were included. We assessed EoR, neurologic outcome, and rate of complications. Progression-free survival (PFS) and overall survival (OS) were calculated with Kaplan–Meier estimations. We used 1% EoR and 1-cm3 steps to detect a threshold for a minimal EoR …

CounselingMaleOncologymedicine.medical_specialtyMultivariate statisticsExtent of resectionNeurosurgical Procedures03 medical and health sciences0302 clinical medicineInternal medicinemedicineOverall survivalHumansSingle-Blind MethodIn patientAgedRetrospective StudiesBrain Neoplasmsbusiness.industryProportional hazards modelOpen surgerySubtotal ResectionMiddle Agedmedicine.diseaseSurvival RateTreatment Outcome030220 oncology & carcinogenesisFemaleSurgeryNeurology (clinical)Glioblastomabusiness030217 neurology & neurosurgeryGlioblastomaWorld Neurosurgery
researchProduct